

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: NEUHOLD et al.	)	Group Art Unit: 1632
Application No.: 09/717,450	;. )	Examiner: Wilson, Michael C.
Filed: November 20, 2000	)	Confirmation No.: 5417
For: TRANSGENIC ANIMAL MODEL FOR DEGENERATIVE DISEASES OF CARTILAGE	: ) : )	Customer No. 45743 February 8, 2007
Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		

## INFORMATION DISCLOSURE STATEMENT

Sir:

The present application has been allowed, however the Issue Fee has not yet been paid. A Request for Continued Examination and the requisite fee therefor is being filed concurrently herewith.

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, Applicants submit herewith a copy of Form PTO-1449, which lists references not previously of record. In addition, Applicants submit a copy of an International Search Report, dated October 5, 1999, which issued in Applicants' corresponding International Patent Application No. PCT/US1998/27056. The reference cited in the ISR and not previously of record is included in the Form PTO-1449. Copies the listed references, other than U.S. patent documents, are also enclosed.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Attorney for Applicants Registration No.: 53,469

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New York, New York 10112-3800 Facsimile: (212) 218-2200

FORM PTO 1449 (modified)			ATTY DOCKET NO.	APPLICATION NO.				
U.S. DEPARTMENT OF COMMEDICE PATENT AND TRADEMARK OF IGE E  LIST OF REFERENCES CITED BY APPLICANT(S)  (Use several sheets if decessary)  FEB 0 9 2007		ŀ	01997.044100.1 09/717,450					
		\	APPLICANT  NEUHOLD et al.					
		/	FILING DATE November 20, 2000		GROUP 1632			
			·	J.S. PATENT DOCUMENTS				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME		S SUBCLASS	FILING DATE IF APPROPRIATE	
	6,028,245	2/22/00		Wasylyk et al.		18	6/25/98	
	5,917,123	6/29/99		McTiernan et al.		18	3/14/97	
	5,880,327	3/9/99		Lubon et al.		7	9/21/94	
	5,625,124	4/29/97	Falk et al.			3	7/11/94	
		OTHER DOCUME	NT(S)	(Including Author, Title, Date, Pertinent Pages, Etc.)				
Knauper et al. (1997) "The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase interaction" J. Biol. Chem. 272:7608-16								
	Allgood and Eastman (1997) "Chimeric Receptors as Gene Switches" Curr. Opinion Biotech. 8:474-79							
	Bradley and Liu (1996) "Target Practice in Transgenics" Nature Genetics 14:121-23							
Burcin et al. (1999) "Adenovirus-Mediated Regulable Target Gene Expression in vivo" Proc. Natl. Acad. Sci. USA 96:355-60								
Feil et al. (1996) "Ligand-Activated Site-Specific Recombination in Mice" Proc. Natl. Acad. Sci. USA 93:10887-90								
Gossen et al. (1995) "Transcriptional Activation by Tetracyclines in Mammalian Cells" Science 268:1766-69								
Shockett and Schatz (1996) "Diverse Strategies for Tetracycline-Regulated Inducible Gene Expression" Proc. Natl. Acad. Sci. USA 93:5173-76								
Shockett and Schatz (1997) "Switching on Gene Expression" Nature Biotech. 15:220-21								
Wang et al. (1997) "Ligand-Inducible and Liver-Specific Target Gene Expression in Transgenic Mice" Nature Biotech. 15:239-43								
Pirok et al. (1997) "Structural and Functional Analysis of the Chick Chondroitin Sulfate Proteoglycan (Aggrecan) Promoter and Enhancer Region" J. Biol. Chem. 272:11566-74								
Lefebvre et al. (1998) "A New Long Lorm of Sox5 (L-Sox 5), Sox6 and Sox9 are Coexpressed in Chondrogenesis and Cooperatively Activate the Type II Collagen Gene" EMBO J. 17:5718-33								
EXAMINER	R DATE CONSIDERED							

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)	ATTY DOCKET NO.	APPLICATION NO.				
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	01997.044100.1	09/717,450				
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)	APPLICANT  NEUHOLD et al.					
	FILING DATE November 20, 2000	GROUP 1632				
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)						
Apte et al. (1997) "The Matrix Metalloproteinase-14 (MMP-14) Gene Is Structurally Distinct From Other MMP Genes and Is Co-expressed with the TIMP-2 Gene During Mouse Embryogenesis" J. Biol. Chem. 272:25511-17						
Masure et al. (1997) "Production and Characterization of Recombinant Active Mouse Gelatinase B from Eukaryotic Cells and in vivo Effects after Intravenous Administration" Eur. J. Biochem. 244:21-30.						
Matsumoto et al. (1997) "Identification of Soluble Type of Membrane-Type Matrix Metalloproteinase-3 Formed by Alternatively Spliced mRNA" Biochim. Biophys. Acta. 1354:159-70.						
Wang et al. (1991) "Identification of a cis-Acting Sequence in the Collagen II Enhancer Required for Chondrocyte Expression and the Binding of a Chondrocyte nuclear Factor." J. Biol. Chem. 266:19878-81.						
Vikkula et al. (1992) "Structural Analysis of the Regulatory Elements of the Type-II Procollagen gene. Conservation of Promoter and First Intron sequences Between Human and Mouse" Biochem J. 285:287-94.						
EXAMINER	DATE CONSIDERED					

Sheet 2 of 2

NY\_MAIN 574646v1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.